

Resource Summary Report

Generated by PRECISE-TBI on Aug 10, 2026

CD317 (PDCA-1)-PerCP-Vio700, mouse

RRID:AB_2657408

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-112-224, RRID:AB_2657408

Antibody Information

URL: http://antibodyregistry.org/AB_2657408

Proper Citation: Miltenyi Biotec Cat# 130-112-224, RRID:AB_2657408

Target Antigen: CD317 (PDCA-1)

Host Organism: human

Clonality: monoclonal

Comments: Discontinued: 2-2019; Target Distribution dendritic cells; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:150 µg in 1 mL

Antibody Name: CD317 (PDCA-1)-PerCP-Vio700, mouse

Description: This monoclonal targets CD317 (PDCA-1)

Target Organism: mouse

Clone ID: REA818

Antibody ID: AB_2657408

Vendor: Miltenyi Biotec

Catalog Number: 130-112-224

Record Creation Time: 20250819T221948+0000

Record Last Update: 20250820T015047+0000

Ratings and Alerts

No rating or validation information has been found for CD317 (PDCA-1)-PerCP-Vio700, mouse.

Warning: Discontinued: 2021

Discontinued: 2-2019; Target Distribution dendritic cells; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:150 µg in 1 mL

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Hua Y, et al. (2022) Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop. Cancer cell, 40(12), 1600.